NEW YORK, March 20, 2017 /PRNewswire/ --
For today, Stock-Callers.com draws attention to select Drug Manufacturers
Last Friday, shares in La Jolla, California headquartered Orexigen Therapeutics Inc. ended the session 3.76% lower at $4.10. The stock recorded a trading volume of 182,389 shares. The Company's shares have surged 141.18% in the previous three months and 135.63% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.24% and 18.50%, respectively. Furthermore, shares of Orexigen Therapeutics, which focuses on the development of pharmaceutical products, have a Relative Strength Index (RSI) of 47.41.
On March 07th, 2017, Orexigen Therapeutics announced that it will release is corporate and financial results for Q4 and full year 2016 on, March 28th, 2017, before the market opens. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 5:00 p.m. ET. Access our complete research report on OREX for free at:
Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock finished 2.14% higher at $142.08. A total volume of 1.19 million shares was traded, which was above their three months average volume of 597,040 shares. The Company's shares have gained 2.89% in the previous three months. The stock is trading above its 200-day moving average by 9.37%. Moreover, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 38.73.
On March 09th, 2017, Northwell Health's Feinstein Institute for Medical Research and United Therapeutics announced a strategic partnership focused on the application of bioelectronic medicine and cell therapy to cardiology, hypertension, and post-transplant tolerance induction. Under the strategic partnership, United Therapeutics will fund Northwell's efforts in four research and development tracks, while United Therapeutics will bring the results into clinical development. The two organizations are working toward the goal of initial regulatory approvals within five years.
On March 16th, 2017, research firm Credit Suisse initiated an 'Underperform' rating on the Company's stock. The complimentary research report on UTHR can be downloaded at:
Shares in Cupertino, California headquartered DURECT Corp. closed the day 2.06% lower at $0.95. The stock recorded a trading volume of 489,277 shares, which was above its three months average volume of 346,270 shares. The Company's shares are trading below their 50-day moving average by 12.73%. Moreover, shares of DURECT, which researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms, have an RSI of 36.67.
On February 28th, 2017, research firm H.C. Wainwright resumed its 'Buy' rating on the Company's stock, with a target price of $3 per share.
On March 14th, 2017, DURECT announced that total revenues were $3.5 million and net loss was $8.8 million for the three months ended December 31st, 2016, compared to total revenues of $5.2 million and net loss of $5.8 million for the three months ended December 31st, 2015. At December 31st, 2016, the Company's cash and investments were $25.2 million compared to cash and investments of $29.3 million at December 31st, 2015. Debt at December 31st, 2016 was $19.9 million. Register for free on Stock-Callers.com and get access to the latest PDF format report on DRRX at:
Foster City, California headquartered SciClone Pharmaceuticals Inc.'s shares recorded a trading volume of 750,632 shares last Friday, which was higher than their three months average volume of 269,130 shares. The stock closed flat at $9.55. The Company's shares are trading 4.84% below their 50-day moving average. Additionally, shares of SciClone Pharma, which provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the US, and Hong Kong, have an RSI of 40.94.
On March 06th, 2017, SciClone announced that revenues in Q4 2016 were $44.1 million, a 3% increase compared to $42.9 million in Q4 2015. On a GAAP basis, SciClone reported net income in Q4 2016 of $6.4 million, or $0.13 and $0.12 per share on a basic and diluted basis, respectively, compared to net income of $12.5 million, or $0.25 and $0.24 per share on a basic and diluted basis, respectively, for Q4 2015. Download your free research report on SCLN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All